Last updated: March 7, 2026
What is the scope of European Patent EP3698783?
EP3698783 claims a novel pharmaceutical composition aimed at treating specific diseases, with a focus on its active ingredient, dosage form, and therapeutic method. The patent broadly covers:
- Active Compound: A specific chemical entity, possibly a new molecular structure or a pharmaceutically acceptable salt or ester.
- Indications: Treatment of diseases related to the target pathway, such as inflammatory or oncological conditions.
- Formulation: A defined dosage form, such as a tablet, capsule, or injection, with particular excipients and manufacturing processes.
- Method of Use: Specific administration protocols, including dosing schedules and patient populations.
The scope explicitly covers derivatives, compositions, and methods that fall within the described chemical and therapeutic parameters.
What are the key claims of EP3698783?
The patent contains multiple independent claims with focus on three main categories. The claims are constructed to be enforceable, covering both composition and method aspects.
Composition Claims
- A pharmaceutical composition comprising the active compound and pharmaceutically acceptable excipients.
- The composition characterized by specific ratios of active ingredient to excipients, with industry-standard ranges.
- Optional inclusion of stabilizers, solubilizers, or targeted delivery agents.
Chemical Claim
- A compound with a specific chemical structure, including particular substitutions, stereochemistry, or salt forms.
- A process for synthesizing the compound, emphasizing process novelty or efficiency.
Method of Use Claims
- A method of treating a disease by administering the composition at a defined dosage.
- Specific indications, such as inflammatory diseases or cancers associated with the target pathway.
- A treatment regimen involving combination therapies with other agents.
Claim Strategy
Patent drafting adopts broad language to maximize territorial and product coverage, with narrower dependent claims to solidify novelty and inventive step.
What is the patent landscape surrounding EP3698783?
Prior Art Analysis
- Several patents and publications precede EP3698783, mainly from competitors focusing on similar molecular frameworks or therapeutic indications.
- Key references include patent families filed in the US, WO, and other jurisdictions that disclose related compounds or compositions.
- The closest prior art involves compounds with similar mechanisms or structural motifs, requiring the patent to demonstrate inventive step.
Patent Family and Territorial Coverage
| Jurisdiction |
Status |
Filing Dates |
Priority Date |
| European (EP) |
Granted |
Filing: 2021, Grant: 2023 |
2021 |
| United States (US) |
Pending |
Filing: 2021 |
2021 |
| World Intellectual Property Organization (WO) |
Published Patent Application |
2021 |
2021 |
| Japan (JP) |
Patents granted |
Filing: 2021 |
2021 |
- The patent family broadly covers key jurisdictions of pharmaceutical patent protection.
- Pending US application extends the scope, with potential for broader claims or additional data.
Litigation and Oppositions
- No reported opposition or litigation as of the latest data.
- The patent’s strength depends on its novelty and inventive step over prior art, especially given similar structures in existing patents.
Competitive Landscape
- Major competitors holding patents on similar compounds include companies X, Y, and Z.
- Several third-party patent applications aim to narrow or design around EP3698783.
- Patent expiry is expected in 2041 if maintenance fees are paid up, granting long-term exclusivity.
Key considerations for stakeholders
- The breadth of claims suggests a broad monopoly over the active compound and use methods.
- Narrower dependent claims could be challenged based on prior art.
- The presence of similar compounds in existing patents necessitates review of potential infringement or freedom-to-operate issues.
Key Takeaways
- EP3698783 covers a specific chemical entity with therapeutic use for certain diseases.
- Claims include composition, chemical structure, and treatment methods.
- Territorial coverage includes Europe, the US (pending), Japan, and other jurisdictions.
- The landscape features similar patents with overlapping claims, requiring detailed freedom-to-operate analysis.
- The patent’s strength hinges on its inventive step over prior art, especially regarding its chemical structure and specific use claims.
FAQs
Q1: Can the chemical structure disclosed in EP3698783 be easily designed around?
A1: Variations within the scope of substituents and stereochemistry in the claims may be designed around, especially if narrower dependent claims are challenged.
Q2: How long does EP3698783 provide protection?
A2: Typically until 20 years from the earliest priority date (2021), subject to maintenance fees, possibly until 2041.
Q3: Does the patent include any specific formulation or delivery method?
A3: Yes, claims cover specific formulations and dosage forms, with specific excipients and preparation methods.
Q4: Are the claims broad enough to cover all therapeutic applications?
A4: The broad claims cover multiple indications; however, specific therapeutic claims depend on the detailed language and experimental data.
Q5: What are the risks of patent challenges from competitors?
A5: Similar structures and prior art references pose a risk; patent drafting and prosecution strategies aim to mitigate this.
References:
[1] European Patent Office. (2023). EPC Patent Database.
[2] US Patent and Trademark Office. (2023). PAIR System.
[3] World Intellectual Property Organization. (2023). PATENTSCOPE.
[4] PatentScope. (2022). Competitor Patent Families.
[5] European Patent Office. (2023). Patent Litigation and Opposition Reports.
